# US 7,745,490 B2 · Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,490 B2
- Document ID: US7745490B2
- Status: Granted
- Kind: B2
- Application number: 11/328,748
- Filed: 2006-01-09
- Published: 2006-09-07
- Granted: 2010-06-29
- Earliest claimed: 2004-05-12
- Assignees: Proteotech, Inc.
- Inventors: Alan D. Snow; Beth P. Nguyen; Thomas P. Lake; Gerardo M. Castillo; Manfred Weigele
- Web page: https://patentgrep.com/patent/US7745490B2

## CPC

- C07C 311/08: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable derivatives, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided.

## Claims

### Claim 1

A compound selected from:
or a pharmaceutically-acceptable salt thereof, wherein M is S(O)2, Rx is alkyl, and
R1, R2, R3 and R4 are each independently selected from OH, —NR5C(═O)R6 and —NR7S(O2)R8, wherein R5 and R7 are each independently hydrogen or alkyl, and R6 and R8 are alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein, R5 is isopropyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein Rx is methyl.

### Claim 4 (depends on 1)

The compound of claim 1 selected from

### Claim 5 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, and a pharmaceutically acceptable excipient.

### Claim 6 (depends on 1)

The compound of claim 1 selected from:

### Claim 7 (depends on 1)

The compound of claim 1, wherein R1, R2, R3 and R4 are OH.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R5 is hydrogen.